Journal Detail - WANFANG MED ONLINE

China Oncology

ISSN:: 1007-3639

CN:: 31-1727/R

Founded in:: 1991

Sponsor:: 中华人民共和国教育部

Indexed in:: EMBase ISTIC PKU CSCD

Email:: zgazzz@china-oncology.com

Publication presents

《中国癌症杂志》主要报道国内外肿瘤学领域前沿的研究内容，包括肿瘤的临床医学、基础医学、流行病学等研究内容。开设栏目包括：专家述评、论著、综述、论著选登、临床病理讨论、个案报道、指南与共识等。目前已被《中文核心期刊要目总览》（北大中文核心期刊）、中国科技论文统计源期刊(中国科技核心期刊)数据库、《中文生物医学期刊文献数据库-CMCC》、《中国生物医学期刊引文数据库-CMCI》、《中国生物文献数据库》、瑞典DOAJ数据库、荷兰SCOPUS数据库、荷兰《医学文摘》（EMBASE）、美国《化学文摘》（CA）、美国EBSCO数据库、日本科技振兴机构数据库（JST）、波兰《哥白尼索引》以及WHO西太平洋地区医学索引（WPRIM）等数据库收录。2012年被评为《复旦大学学位与研究生教育国内期刊指导目录》A类期刊。

Latest updates

1: 观察性流行病学研究的报告指南——STROBE声明 (《中国癌症杂志》编辑部)
2: Application progress and challenges of artificial intelligence in organoid research (吴洪基王海霞汪玲罗小刚邹冬玲)
3: Research progress on the correlation between imaging features and the molecular subtype,histopathology,clinical prognosis of ductal carcinoma in situ of the breast (刘琪常才李佳伟)
4: Progress of important clinical research of breast cancer in China in 2023 (张琪修秉虬吴炅)
5: Expert consensus on population-based BRCA germline mutation screening in China(2024 edition) (中国抗癌协会肿瘤标志物专业委员会上海市抗癌协会肿瘤标志物专业委员会卢仁泉郭玮关明)
6: Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer (胡晓钰蔡毓文叶富贵邵志敏胡伟刚余科达)
7: 《中国癌症杂志》被EMBASE数据库收录 (《中国癌症杂志》编辑部)
8: Important research progress in clinical practice for advanced breast cancer in 2023 (张思源江泽飞)
9: KDM4A promotes the migration and invasion of breast cancer cell line MDA-MB-231 by downregulating BMP9 (陈远香余涛杨诗雨曾涛魏兰张彦)
10: Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer (刘志昱徐栋陈西昊李纪鹏)
11: Important research progress in clinical practice for early breast cancer in 2023 (王昭卜黎星于鑫淼金锋)
12: Efficacy,metabolic characteristics,safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer:a multicenter,randomized,double-blind phase Ⅲ equivalence trial (罗扬孙涛邵志敏崔久嵬潘跃银张清媛程颖李惠平杨燕叶长生于国华王京芬刘运江刘新兰周宇红柏玉举谷元廷王晓稼徐兵河宋礼华)
13: 编者的话 (邵志敏江一舟)
14: 《中国癌症杂志》长摘要写作要求 (《中国癌症杂志》编辑部)

All Issues

2024:

2023:

2022:

2021:

2020:

2019:

2018:

2017:

2016:

2015:

2014:

2013:

2012:

2011:

2010:

2009:

2008:

2007:

2006:

2005:

2004:

2003:

2002:

2001:

2000:

China Oncology